Shipping Challenges: Kedrion's Vital Deliveries Through Hormuz
Italian biopharmaceutical company Kedrion is facing challenges in delivering plasma-based medicines to Iran due to potential shipping disruptions in the Strait of Hormuz. CEO Ugo Di Francesco highlights the rising logistics costs and the necessity for land transportation, despite no current significant effects on product availability.
Italian biopharmaceutical giant Kedrion is encountering potential issues delivering vital plasma-based medicines to Iranian patients, as shipping through the crucial Strait of Hormuz may be disrupted.
In an interview with Reuters, CEO Ugo Di Francesco disclosed that the company is adapting by using land routes to transport immunoglobulins to Iran. This adjustment is necessary due to escalating fuel prices, which threaten to make logistics prohibitively expensive.
'It's a question of logistics, namely our ability to physically deliver products to patients,' Di Francesco stated. Despite the challenges, the company reported no significant impact on its ability to provide life-saving treatments yet.
(With inputs from agencies.)
ALSO READ
Diplomatic Deadlock: U.S. and Iran Peace Talks Falter
Diplomatic Maneuvering: Iran's Araghchi Leaves Islamabad Amid Uncertain Peace Talks
Diplomatic Setback: U.S. and Iran Talks Stumble in Islamabad
Trump Halts US-Iran Talks in Everlasting Gulf Conflict
Trump Cancels Key Envoys' Pakistan Trip for Iran Talks

